Abstract:BackgroundYes-associated protein 1 (YAP1) is an effector of Hippo pathway, which is critical for regulating organ size, cell proliferation and tumor growth in mammals. Many previous studies have explored the relationship between YAP1 and various types of cancer. However, these studies were limited by the small samples size and the findings were inconsistent among them. Therefore, a meta-analysis was conducted to assess the association between YAP1 and malignancies.MethodsA systematic literature search was conducted for eligible studies in the PubMed, Corchane Library, Web of Knowledge, EMBASE and CBM disc databases from inception to August 1st 2014. After heterogeneity analysis, pooled harzad ratio (HR) with 95% confidence interval (95% CI) using both fixed and random effect models were estimated in STATA 10.0. Meta regression analysis, subgroup analysis and sensitivity analysis were performed to explore the potential sources of heterogeneity and to evaluate the robustness of the result. Publication bias was assessed by Egger's test and funnel plot.ResultsA total of 21 unique articles from 2009 to 2014, comprising 2983 patients, were analyzed in the meta-analysis. The association of YAP1 expression and overall survival time (OS) was evaluated in 20 studies including 2067 patients. Positive YAP1 showed poorer OS (HR = 1.826; 95% CI = 1.465-2.275; p < 0.002). For evaluating disease-free survival time (DFS), 10 studies with 1139 patients were analyzed. Positive YAP1 indicated worse DFS (HR = 2.114; 95% CI = 1.406-3.179; p < 0.001). Subgroup analysis showed that both positive nuclear YAP1 (HR = 1.390, 95% CI: 0.810-2.400, p = 0.729) and up-regulation overall YAP1 (HR = 2.237, 95% CI: 1.548-3.232, p < 0.001) had poorer OS for patients with malignancies. Similarly, both positive nuclear YAP1 (HR = 3.733, 95% CI: 1.469-9.483, p = 0.001) and up-regulation overall YAP1 (HR = 1.481, 95% CI: 1.163-1.886, p = 0.554) showed worse DFS. The patients with urogenital system cancer had the poorest OS (HR = 2.133, 95% CI: 1.549-2.937, p = 0.020). The patients with alimentary system cancer had the most significant impact on DFS (HR = 1.879, 95% CI: 1.537-2.297, p < 0.001).ConclusionBoth overall and nuclear YAP1 overexpression are intimately associated with adverse OS and DFS in numerous cancers, suggesting that YAP1 may act as a potential therapeutic targets of these malignancies in the future.

Data from Genome-Wide Interrogation Identifies <i>YAP1</i> Variants Associated with Survival of Small-Cell Lung Cancer Patients

Genome-Wide Interrogation Identifies <i>YAP1</i> Variants Associated with Survival of Small-Cell Lung Cancer Patients

Genome-Wide Interrogation Identifies Yap1 Variants Associated With Survival Of Small-Cell Lung Cancer Patients

Supplementary Figure 1, Tables 1-2 from Genome-Wide Interrogation Identifies YAP1 Variants Associated with Survival of Small-Cell Lung Cancer Patients

SNP rs17079281 Decreases Lung Cancer Risk Through Creating an YY1-Binding Site to Suppress DCBLD1 Expression

YAP1 Expression is Associated with Survival and Immunosuppression in Small Cell Lung Cancer

YAP1 Mutation As a Novel Predictor of Response to Anti-Pd-1/pd-l1 Treatment in Pan-Cancers.

The Prognostic Value of YAP1 on Clinical Outcomes in Human Cancers

Genetic Variants in Abcg1 Are Associated with Survival of Nonsmall-Cell Lung Cancer Patients

YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.

Novel Genetic Variants of SYK and ITGA1 Related Lymphangiogenesis Signaling Pathway Predict Non-Small Cell Lung Cancer Survival.

Redefining YAP1 in small cell lung cancer: shifting from a dominant subtype marker to a favorable prognostic indicator

Genome-wide Association Study of Survival in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy.

The predictive value of YAP-1 for efficacy of immunotherapy among patients with ES-SCLC.

YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer

Significant association of YAP1 and HSPC111 proteins with poor prognosis in Chinese gastric cancer patients

Gene Regulation Network of Prognostic Biomarker YAP1 in Human Cancers: An Integrated Bioinformatics Study

YAP 1 Regulates ABCG 2 and Cancer Cell Side Population in Human Lung Cancer Cells

Prognostic Value Of Yes-Associated Protein 1 (Yap1) In Various Cancers: A Meta-Analysis

Potentially functional genetic variants in the TNF/TNFR signaling pathway genes predict survival of patients with non-small cell lung cancer in the PLCO cancer screening trial.